# OnCo record ea2197-ivonescimab (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ea2197-ivonescimab/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ea2197-ivonescimab", "NCT07765433" ;
  schema:name "EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer"@en ;
  schema:description "A planned American cooperative-group trial will test whether the PD-1 and VEGF bispecific antibody ivonescimab beats the current immunotherapies when added to first-line chemotherapy for bile duct and gallbladder cancer, with survival as the endpoint."@en ;
  schema:url <https://onco.cc/trials/ea2197-ivonescimab/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07765433> ;
  onco:status "planned" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/> .